SUMMARY The excretion of three oestrogen fractions and progesterone metabolites in 64 female epileptic patients was determined during the menstrual cycle, and in 50 women of this sample serum phenytoin and phenobarbitone levels were measured. A significant decrease of both hormones in epileptic patients was found as compared to a control group. The variations in serum phenytoin levels were greater in females with so-called catamenial epilepsy with a marked fall of drug levels between days 27 and 28 corresponding with an increase of seizure frequency. The effect of progesterone deficit on seizure susceptibility before menstrual bleeding is discussed, and the need of serum anticonvulsant level determination during the premenstrual phase in epileptic women is suggested. 
The relation between sex hormones and epilepsy has not yet been fully explained. The hormones are known not only to play a role in brain seizure activity but also to interact with antiepileptic drugs. The neuroendocrine system has an influence on seizure incidence mainly in women because of rhythmic hormone activity changes in the hypothalamuspituitary-gonadal axis. There are considerable discrepancies regarding the incidence of seizures in the premenstrual phase ranging from 10 to 70% of female epileptics. ' 3 In our study analysis of nearly 7000 seizures during 1200 menstrual cycles has shown such a correlation in two-thirds of patients.4 Numerous experimental investigations have shown a convulsive effect of oestrogens and an inhibitory effect of progesterone on brain seizure activity,5-7 but the role of ovarian hormones in seizure incidence during the premenstrual stage in women still remains unclear.
Evaluation of the relation between seizures and the menstrual cycle should also include possible fluctuations of serum anticonvulsant levels. This study was undertaken to investigate whether there is a correlation between ovarian steroid hormones, antiepileptic drug levels and seizure incidence during the menstrual cycle in long-term treated female epileptic patients. Twenty-four urinary excretions of oestrone (E,), oestradiol (E2) and oestriol (E3) were estimated by column 22, 27 and 28. Results were compared with control values obtained from nine healthy females in the same age range who had examinations performed in our laboratory during normal menstrual cycles. In 50 patients (29 from Group A and 21 from Group B) serum levels of phenytoin and phenobarbitone were determined on the same days of cycle. Blood samples were collected 3 hours after the morning drug administration and serum level was measured by spectrophotometry.'0 The coefficients of variation (V) for this method were 3% (n = 35) for phenytoin and 4% (n = 35) for phenobarbitone. In addition, function of the liver and kidneys as well as total protein and protein fractions were evaluated in all the patients by routine methods. The data were analysed statistically using Student's 
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Discussion
The results obtained in this study do not confirm the opinion" '3 that a possible catamenial increase of seizure frequency is due to greater oestrogen activity during the premenstrual period '3 or at the time of the oestrogen peak during ovulation.5 We found that the values of this hormone were nearly the same on days of both high and low seizure incidence.
There was a decrease in oestrogens on preovulatory and premenstrual days as compared to control values. The analysis of progesterone metabolite measurements suggests that seizure incidence during the menstrual cycle is connected with a deficit of this hormone rather than with elevated oestrogen levels. Our hypothesis is based on the anticonvulsant properties of progesterone and the negative correlation between seizure incidence and amounts of pregnanediol in female epileptics. It should be mentioned that the lowest number of seizures was noted when progesterone reached its highest level (day 22). Although pregnanediol values were higher on days 27 and 28 than on days 5 and 6, the difference between the results in patients and controls was greater on two premenstrual days than on days of follicular stage. This was also accompanied by difference in seizure incidence between the two cycle phases (33 seizures on days 5 and 6, and 60 seizures on days 27 and 28). This result was in agreement with our preliminary study in which ovarian hormones were determined two days before menstrual bleeding. '4 The "protective effect" of progesterone on brain seizure activity in women can be confirmed by the use of synthetic progesterone in the therapy for catamenial epilepsy. Recently, Mattson etall5 have observed a reduction of seizure frequency in 7 of 10 women treated with medroxyprogesterone. The results of serum LH determinations by RIA during the menstrual cycle in the same population studied confirmed the presence of changes in progesterone activity. '6 We suppose that the luteal deficit and, in consequence, a decrease in progesterone secretion together with a greater number of unovulatory cycles, as shown by cytohormonal smears, '' may be one of the factors responsible for a lower fertility index in female epileptics than in the general population. ' 8 Furthermore, there is a possibility that a reduced antiepileptogenic effect of progesterone may be among the causes of increased seizure reactivity before menstrual bleeding. It is also possible that the convulsive susceptibility increases before menstruation in the vast majority of women with epilepsy because progesterone deficit was found in females with fits both related and unrelated to premenstrual phase. However the risk of seizure incidence is greater in women with so-called catamenial epilepsy. It should be recognised, however, that in individual cases the seizure occurrence at the time of increased premenstrual convulsive predisposition may also depend on other than hormonal factors.
Variations in drug levels during the menstrual cycle and their influence on seizure incidence should also be taken'into consideration. Backstrom and Jorpes '9 found slight fluctuation in phenytoin, phenobarbitone and carbamazepine levels during two out of nine menstrual cycles in seven women. In our study the phenytoin levels were not constant during the menstrual cycle but showed a tendency to fluctuate. In the whole sample half of the females had a coefficient of variation in the range of 15-44%. Variability of phenytoin serum levels in particular phases of cycle suggest the influence of the changes in ovarian hormone activity on drug metabolism. According to Cereghino, 20 
